Evidence map›Paper›PMID 38212967›Full record

ArticleApplied microbiology and biotechnology2024

Activity of thonningianin A against Candida albicans in vitro and in vivo.

Hui Wang, Hui Li, ZhiWei Liu, ZhenYu Zhu, YingYing Cao

Open access · goldAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hui Wang *Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, China.
Hui Li *Department of Dermatology, Changhai Hospital, Naval Medical University, Shanghai, 200438, China.
ZhiWei LiuShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, China.
ZhenYu ZhuSchool of Pharmacy, Naval Medical University, Shanghai, 200433, China. zzyzyfzhu@163.com.
YingYing CaoShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, China. caoyingying608@163.com.ORCID http://orcid.org/0009-0001-8035-1411
Tongji University · CNSecond Military Medical University · CNUnited States Department of the Navy · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungal infections are increasing rapidly, and antifungal agents used in clinics are limited. Therefore, novel antifungal agents with high efficiency are urgently required. In this study, we investigated the antifungal activity of thonningianin A (THA), a natural compound that is widely found in plants. We first determined the activity of THA against Candida albicans, one of the most common fungal pathogens, and found that THA showed antifungal activity against all C. albicans tested, including several fluconazole-resistant isolates. THA also inhibits the growth of non-Candida albicans species. In addition, THA displayed antibiofilm activity and could not only inhibit biofilm formation but also destroy mature biofilms. The in vivo antifungal efficacy of THA was confirmed in a Galleria mellonella infection model. Further studies revealed that THA could enhance intracellular reactive oxygen species (ROS) production and regulate the transcription of several redox-related genes. Specifically, caspase activity and expression of CaMCA1, a caspase-encoding gene in C. albicans, were remarkably increased upon THA treatment. Consistent with this, in the presence of THA, the Camca1 null mutant displayed higher survival rates and reduced caspase activity compared to the wild-type or CaMCA1-reintroduced strains, indicating an important role of CaMCA1 in the antifungal activity of THA. Taken together, our results indicate that THA possesses excellent antifungal activity and may be a promising novel antifungal candidate. KEY POINTS: • THA exhibits activity against Candida species, including fluconazole-resistant isolates • THA inhibits biofilm formation and destroys mature biofilm • Elevated ROS production and CaMCA1-mediated caspase activity are involved in the antifungal mechanisms of THA.

Indexed as

Antifungal AgentsCandida albicansHydrolyzable TanninsBiofilmsCaspasesFluconazoleMicrobial Sensitivity TestsReactive Oxygen SpeciesAntifungal AgentsCaspasesFluconazoleHydrolyzable TanninsReactive Oxygen Speciesthonningianin AAntifungalCaMCA1Candida albicansROSThonningianin A

Identifiers

PMID38212967
PMCPMC10784352
OpenAlexW4390751410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.